Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PBCAR269A |
| Trade Name | |
| Synonyms | Allogeneic Anti-BCMA-CAR T-cells PBCAR269A |
| Drug Descriptions |
PBCAR269A are allogeneic T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeted against B-cell maturation antigen (BCMA), potentially resulting in increased death of tumor cells expressing BCMA (NCI Drug Dictionary). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C171066 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Fludarabine + Nirogacestat + PBCAR269A | Cyclophosphamide Fludarabine Nirogacestat PBCAR269A | 0 | 1 |
| Cyclophosphamide + Fludarabine + PBCAR269A | Cyclophosphamide Fludarabine PBCAR269A | 0 | 1 |
| PBCAR269A | PBCAR269A | 0 | 0 |